特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
933276

中国の医薬品受託製造サービス市場:(2020年~2030年)

China Pharmaceutical Contract Manufacturing Services Market, 2020-2030

出版日: | 発行: ROOTS ANALYSIS | ページ情報: 英文 210 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.84円
中国の医薬品受託製造サービス市場:(2020年~2030年)
出版日: 2020年03月31日
発行: ROOTS ANALYSIS
ページ情報: 英文 210 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

中国の製薬市場は、2020年には3,000億米ドルを超えると見込まれており、それに伴い、医薬品受託製造市場は有望なセグメントとして顕著な成長を遂げています。新型コロナウイルス感染症が発生し、製薬会社はの本格的な事業を再開により、大規模な医薬品受託製造の需要が大幅に増加すると予測されています。

洞察の例

当レポートは中国の医薬品受託製造サービスについて調査しており、市場機会や動向、成長および抑制要因、地域、製品タイプ・メーカー規模・事業規模別の市場分析、競合情勢、新型コロナウイルス感染症の影響、主要企業のプロファイル等の情報を提供しています。

目次

第1章 概要

第2章 エグゼクティブサマリー

第3章 イントロダクション

  • 章の概要
  • 医薬品受託製造の概要
  • 医薬品受託製造業の進化
    • 従来のCMO
    • 現在のCMO
  • 製薬業界におけるアウトソーシングの必要性
  • CMOが提供するサービス
  • 中国の製薬契約製造シナリオ
  • 中国に拠点を置くCMOへの医薬品製造のアウトソーシングに関連する利点と課題

第4章 ケーススタディ:小分子と大分子の比較

  • 章の概要
  • 小分子および大分子の薬剤/治療
    • 主な特性の比較
    • 製造工程の比較
    • 製造関連の主な課題の比較

第5章 市場概要

  • 章の概要
  • 中国に製造施設を持つ中国の製薬CMO:企業のリスト
  • 中国に製造施設を持つ中国以外の製薬CMO:企業のリスト
    • 設立年別分析
    • 会社規模別分析
    • 本社所在地別分析
    • 製品タイプ別の分析(APIおよびFDF)
    • 最大営業規模別分析
    • FDFタイプ別分析

第6章 中国の製薬CMOの製造施設

  • 章の概要
  • 中国の製薬CMO製造施設
    • 中国東部の施設
    • 中国北部の施設
    • 中国南部の施設

第7章 中国の医薬品製造規制

  • 章の概要
    • 中国の保健当局
    • 中国の規制ガイドラインの概要

第8章 企業プロファイル

  • 章の概要
  • 2Y-Chem
  • Aurisco Pharmaceutical
  • ChemPartner
  • Dorrapharma
  • Hubei Biocause Pharmaceutical
  • Infoark
  • Ningbo Menovo Pharmaceutical
  • Shandong Xinhua Pharmaceutical
  • Shanghai Acebright Pharmaceuticals
  • STA Pharmaceutical
  • Zhejiang Huahai Pharmaceutical

第9章 中国での大手製薬会社イニシアチブ

  • 章の概要
  • 大手製薬会社:イニシアチブのリスト
  • 大手製薬企業:ベンチマーク分析

第10章 ケーススタディ:最近の提携の動向

  • 章の概要
  • 提携モデル
  • 中国の製造施設を持つCMO:最近の提携企業のリスト
  • 中国の製造施設を持つCMO:提携企業マップ

第11章 生産能力分析

  • 章の概要
  • 主な前提条件と調査手法
  • 中国に製造施設を持つCMO:設備能力

第12章 SWOT分析

第13章 市場予測

  • 章の概要
  • 予測調査手法と主要な仮定
  • 中国における医薬品受託製造サービス市場:2020~2030年
  • 市場分析:地域別
    • 中国東部
    • 中国南部
    • 中国北部
  • 市場分析:製品タイプ別
    • API契約製造
    • 医薬品契約製造
  • 市場分析:事業規模別
    • 臨床規模
    • 商業規模
  • 市場分析:メーカー規模別
    • 小規模企業のシェア
    • 中規模企業のシェア
    • 大企業/超大企業のシェア
  • 結論

第14章 ケーススタディ:新型コロナウイルス感染症の影響

  • 章の概要
  • 影響の評価
    • 主要企業の率先および意見
    • 中国製薬CMO市場機会への影響
  • 採用する主な戦略:鳥瞰図
    • 即時ステップ
    • 短期/長期のステップ

第15章 結論

第16章 付録1:集計データ

第17章 付録2:企業・組織のリスト

図表

List Of Figures

  • Figure 3.1 Outsourcing across Various Components of the Pharmaceutical Value Chain
  • Figure 3.2 Range of Services Offered by CMOs
  • Figure 4.1 Small Molecule and Large Molecule Drugs: Comparison of Key Characteristics
  • Figure 4.2 Small Molecules versus Large Molecule: Comparison of Manufacturing Process
  • Figure 5.1 Chinese Pharmaceutical CMOs: Distribution by Year of Establishment
  • Figure 5.2 Chinese Pharmaceutical CMOs: Distribution by Company Size
  • Figure 5.3 Chinese Pharmaceutical CMOs: Distribution by Location of Headquarters (Region-wise)
  • Figure 5.4 Chinese Pharmaceutical CMOs: Distribution by Location of Headquarters (Province-wise)
  • Figure 5.5 Chinese Pharmaceutical CMOs: Distribution by Type of Product
  • Figure 5.6 Chinese Pharmaceutical CMOs: Distribution by Type of Product Manufactured and Location of Headquarters
  • Figure 5.7 Chinese Pharmaceutical CMOs: Highest Scale of Operation
  • Figure 5.8 Chinese Pharmaceutical CMOs: Distribution by Type of FDF Manufactured
  • Figure 5.9 Chinese Pharmaceutical CMOs: Distribution by Type of Solid FDF Manufactured
  • Figure 5.10 Chinese Pharmaceutical CMOs: Distribution by Type of Liquid FDF Manufactured
  • Figure 5.11 Chinese Pharmaceutical CMOs: Distribution by Type of Powder FDF Manufactured
  • Figure 5.12 Chinese Pharmaceutical CMOs: Distribution by Type of Semi-Solid FDF Manufactured
  • Figure 5.13 Chinese Pharmaceutical CMOs: Distribution by Type of FDF Manufactured and Geography
  • Figure 5.14 Chinese Pharmaceutical CMOs: Distribution by Type of Primary Packaging
  • Figure 5.15 Non-Chinese Pharmaceutical CMOs: Distribution by Year of Establishment
  • Figure 5.16 Non-Chinese Pharmaceutical CMOs: Distribution by Company Size
  • Figure 5.17 Non-Chinese Pharmaceutical CMOs: Distribution by Location of Headquarters (Region-wise)
  • Figure 5.18 Non-Chinese Pharmaceutical CMOs: Distribution by Location of Headquarters (Country-wise)
  • Figure 5.19 Non-Chinese Pharmaceutical CMOs: Distribution by Type of Product
  • Figure 5.20 Non-Chinese Pharmaceutical CMOs: Distribution by Type of Product Manufactured and Geography
  • Figure 5.21 Non-Chinese Pharmaceutical CMOs: Distribution by Highest Scale of Operation
  • Figure 5.22 Non-Chinese Pharmaceutical CMOs: Distribution by Type of FDF Manufactured
  • Figure 5.23 Non-Chinese Pharmaceutical CMOs: Distribution by Type of Solid FDF Manufactured
  • Figure 5.24 Non-Chinese Pharmaceutical CMOs: Distribution by Type of Liquid FDF Manufactured
  • Figure 5.25 Non-Chinese Pharmaceutical CMOs: Distribution by Type of Powder FDF Manufactured
  • Figure 5.26 Non-Chinese Pharmaceutical CMOs: Distribution by Type of FDF Manufactured and Geography
  • Figure 6.1 Geographical Map Representation: Pharmaceutical CMO Manufacturing Facilities in Eastern China
  • Figure 6.2 Pharmaceutical CMO Manufacturing Facilities in Eastern China: Distribution by Company Size and Type of Product
  • Figure 6.3 Geographical Map Representation: Pharmaceutical CMO Manufacturing Facilities in Northern China
  • Figure 6.4 Pharmaceutical CMO Manufacturing Facilities in Northern China: Distribution by Company Size and Type of Product
  • Figure 6.5 Geographical Map Representation: Pharmaceutical CMO Manufacturing Facilities in Southern China
  • Figure 6.6 Pharmaceutical CMO Manufacturing Facilities in Southern China: Distribution by Company Size and Type of Product
  • Figure 7.1 Health Authorities in China and Affiliated Organizations of the CFDA
  • Figure 7.2 Organizational Structure of the CDE
  • Figure 7.3 Responsibilities of the Contract Giver
  • Figure 7.4 Important Aspects of the Contract
  • Figure 9.1 Big Pharma Benchmarking: Distribution by Number of Initiatives
  • Figure 9.2 Big Pharma Players: Distribution by Year of Initiative
  • Figure 9.3 Big Pharma Players: Distribution by Company and Year of Initiative
  • Figure 9.4 Big Pharma Players: Distribution by Type of Initiative
  • Figure 9.5 Harvey Ball Analysis: Summary of Investments Made
  • Figure 9.6 Big Pharma Players: Geographical Distribution by Investments Made (Facility Specific)
  • Figure 10.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-February 2020
  • Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 10.3 Partnerships and Collaborations: Local and International Distribution
  • Figure 10.4 Partnerships Landscape: Distribution by Year of Collaboration, Type of Collaboration and Collaborator
  • Figure 11.1 Pharmaceutical Contract Manufacturing Installed Capacity in China: Distribution by Size of CMOs
  • Figure 11.2 Pharmaceutical Contract Manufacturing Installed Capacity in China: Distribution by Location of Facility
  • Figure 11.3 Capacity Analysis: Contract Pharmaceutical Capacity in Eastern China
  • Figure 11.4 Capacity Analysis: Contract Pharmaceutical Capacity in Southcentral China
  • Figure 11.5 Capacity Analysis: Contract Pharmaceutical Capacity in Northern China
  • Figure 12.1 China Pharmaceutical Contract Manufacturing Services Market: SWOT Analysis
  • Figure 12.2 Comparison of SWOT Factors: Harvey Ball Analysis
  • Figure 13.1 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
  • Figure 13.2 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030, Distribution by Geography: Base Scenario (USD Billion)
  • Figure 13.3 Pharmaceutical Contract Manufacturing Services Market in Eastern China, 2020-2030: Base Scenario (USD Billion)
  • Figure 13.4 Pharmaceutical Contract Manufacturing Services Market in Southern China, 2020-2030: Base Scenario (USD Billion)
  • Figure 13.5 Pharmaceutical Contract Manufacturing Services Market in Northern China, 2020-2030: Base Scenario (USD Billion)
  • Figure 13.6 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030, Distribution by Type of Product (USD Billion)
  • Figure 13.7 API Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
  • Figure 13.8 API Contract Manufacturing Services Market in China, Distribution by Geography, 2020-2030: Base Scenario (USD Billion)
  • Figure 13.9 API Contract Manufacturing Services Market in Eastern China, 2020-2030: Base Scenario (USD Billion)
  • Figure 13.10 API Contract Manufacturing Services Market in Southern China, 2020-2030: Base Scenario (USD Billion)
  • Figure 13.11 API Contract Manufacturing Services Market in Southern China, 2020-2030: Base Scenario (USD Billion)
  • Figure 13.12 Drug Product Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
  • Figure 13.13 Drug Product Contract Manufacturing Services Market in China, Distribution by Geography, 2020-2030: Base Scenario (USD Billion)
  • Figure 13.14 Drug Product Contract Manufacturing Services Market in Eastern China, 2020-2030: Base Scenario (USD Billion)
  • Figure 13.15 Drug Product Contract Manufacturing Services Market in Southern China, 2020-2030: Base Scenario (USD Billion)
  • Figure 13.16 Drug Product Contract Manufacturing Services Market in Northern China, 2020-2030: Base Scenario (USD Billion)
  • Figure 13.17 Drug Product Contract Manufacturing Services Market in China, Distribution by Type of Drug Product, 2020-2030, Base Scenario (USD Billion)
  • Figure 13.18 Drug Product Contract Manufacturing Services Market in China, 2020-2030, Share of Solid Drug Product: Base Scenario (USD Billion)
  • Figure 13.19 Drug Product Contract Manufacturing Services Market in China, 2020-2030, Share of Liquid and Semi Solid Drug Product: Base Scenario (USD Billion)
  • Figure 13.20 Drug Product Contract Manufacturing Services Market in China, 2020-2030, Share of Injectable Drug Product: Base Scenario (USD Billion)
  • Figure 13.21 Drug product Contract Manufacturing Services Market in China, 2020-2030, Share of Other Drug Products: Base Scenario (USD Billion)
  • Figure 13.22 Pharmaceutical Contract Manufacturing Services Market in China, Distribution by Scale of Operation, 2020-2030, Base Scenario (USD Billion)
  • Figure 13.23 Clinical Scale Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
  • Figure 13.24 Commercial Scale Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
  • Figure 13.25 Pharmaceutical Contract Manufacturing Services Market in China, Distribution by Size of Manufacturers, 2020-2030, Base Scenario (USD Billion)
  • Figure 13.26 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030, Share of Small Companies: Base Scenario (USD Billion)
  • Figure 13.27 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030, Share of Mid-sized Companies: Base Scenario (USD Billion)
  • Figure 13.28 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030, Share of Large / Very Large Companies: Base Scenario (USD Billion)
  • Figure 14.1 Pharmaceutical Contract Manufacturing Services Market in China, 2015-2030: COVID Impact Scenario (USD Billion)
  • Figure 14.2 Financial Leadership vs Strategic Leadership Matrix: Evaluation of Preparedness of Companies
  • Figure 15.2 China Pharmaceutical Contract Manufacturing Services Market: Key Takeaways

List Of Tables

  • Table 3.1 Preferred Locations for Pharmaceutical CMO / CDMO Services
  • Table 4.1 Small Molecule and Large Molecule Drugs: Comparison of Development Characteristics
  • Table 5.1 List of Chinese Pharmaceutical CMOs: Information on Year of Establishment, Company Size, Location of Headquarters, Type of Product and Scale of Operation
  • Table 5.2 List of Chinese Pharmaceutical CMOs: Information on Type of FDF Manufactured
  • Table 5.3 List of Chinese Pharmaceutical CMOs: Information on Packaging Service
  • Table 5.4 List of Non-Chinese Pharmaceutical CMOs: Information on Year of Establishment, Company Size, Headquarter Location and Type of Product and Scale of Operation
  • Table 5.5 List of Chinese Pharmaceutical CMOs: Information on Type of FDF Manufactured
  • Table 6.1 Pharmaceutical CMO Manufacturing Facilities in China: Information on Location of Facilities
  • Table 6.2 Pharmaceutical CMO Manufacturing Facilities in Eastern China: Information on Location of Facilities (Province-Wise) and Core Capability
  • Table 6.3 Pharmaceutical CMO Manufacturing Facilities in Northern China: Information on Location of Facilities (Province-Wise) and Core Capability
  • Table 6.4 Pharmaceutical CMO Manufacturing Facilities in Southern China: Information on Location of Facilities (Province-Wise) and Core Capability
  • Table 8.1 2-Y Chem: Company Overview
  • Table 8.2 2Y-Chem: Pharmaceutical R&D and Manufacturing Service Offerings
  • Table 8.3 Aurisco Pharmaceutical: Company Overview
  • Table 8.4 Aurisco Pharmaceutical: R&D and Pharmaceutical Manufacturing Service Offerings
  • Table 8.5 ChemPartner: Company Overview
  • Table 8.6 ChemPartner: R&D and Pharmaceutical Manufacturing Service Offerings
  • Table 8.7 Dorrapharma: Company Overview
  • Table 8.8 Dorrapharma: R&D and Pharmaceutical Manufacturing Service Offerings
  • Table 8.9 Hubei Biocasue Pharmaceutical: Company Overview
  • Table 8.10 Hubei Biocasue Pharmaceutical: R&D and Pharmaceutical Manufacturing Service Offerings
  • Table 8.11 Infoark: Company Overview
  • Table 8.12 Ningbo Menovo Pharmaceutical: Company Overview
  • Table 8.13 Shandong Xinhua Pharmaceutical: Company Overview
  • Table 8.14 Shandong Xinhua Pharmaceutical: Pharmaceutical R&D and Manufacturing Service Offerings
  • Table 8.15 Shanghai Acebright Pharmaceuticals: Company Overview
  • Table 8.16 STA Pharmaceutical: Company Overview
  • Table 8.17 STA Pharmaceutical: Pharmaceutical R&D and Manufacturing Service Offerings
  • Table 8.18 Zhejiang Huahai Pharmaceutical: Company Overview
  • Table 8.19 Zhejiang Huahai Pharmaceutical: R&D and Pharmaceutical Manufacturing Service Offerings
  • Table 9.1 Big Pharmaceutical Players: List of Initiatives
  • Table 10.1 List of Partnerships, 2014-Q1 2019
  • Table 10.2 List of Partnerships: Information on Headquarter Location of Parent and Partner Company
  • Table 11.1 China Pharmaceutical Contract Manufacturing Installed Capacity: Average Capacity by Size of CMOs (Sample Data Set)
  • Table 11.2 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Size of CMOs
  • Table 11.3 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Location of Chinese Manufacturing Facility(s)
  • Table 16.1 Chinese Pharmaceutical CMOs: Distribution by Year of Establishment
  • Table 16.2 Chinese Pharmaceutical CMOs: Distribution by Company Size
  • Table 16.3 Chinese Pharmaceutical CMOs: Distribution by Location of Headquarters (Region-wise)
  • Table 16.4 Chinese Pharmaceutical CMOs: Distribution by Location of Headquarters (Province-wise)
  • Table 16.5 Chinese Pharmaceutical CMOs: Distribution by Type of Product
  • Table 16.6 Chinese Pharmaceutical CMOs: Distribution by Highest Scale of Operation
  • Table 16.7 Chinese Pharmaceutical CMOs: Distribution by Type of FDF Manufactured
  • Table 16.8 Chinese Pharmaceutical CMOs: Distribution by Type of Solid FDF Manufactured
  • Table 16.9 Chinese Pharmaceutical CMOs: Distribution by Type of Liquid FDF Manufactured
  • Table 16.10 Chinese Pharmaceutical CMOs: Distribution by Type of Powder FDF Manufactured
  • Table 16.11 Chinese Pharmaceutical CMOs: Distribution by Type of Semi-Solid FDF Manufactured
  • Table 16.12 Chinese Pharmaceutical CMOs: Distribution by Type of Primary Packaging
  • Table 16.13 Non-Chinese Pharmaceutical CMOs: Distribution by Year of Establishment
  • Table 16.14 Non-Chinese Pharmaceutical CMOs: Distribution by Company Size
  • Table 16.15 Non-Chinese Pharmaceutical CMOs: Distribution by Location of Headquarters (Region-wise)
  • Table 16.16 Non-Chinese Pharmaceutical CMOs: Distribution by Location of Headquarters (Country-wise)
  • Table 16.17 Non-Chinese Pharmaceutical CMOs: Distribution by Type of Product
  • Table 16.18 Non-Chinese Pharmaceutical CMOs: Distribution by Highest Scale of Operation
  • Table 16.19 Non-Chinese Pharmaceutical CMOs: Distribution by Type of FDF Manufactured
  • Table 16.20 Non-Chinese Pharmaceutical CMOs: Distribution by Type of Solid FDF Manufactured
  • Table 16.21 Non-Chinese Pharmaceutical CMOs: Distribution by Type of Liquid FDF Manufactured
  • Table 16.22 Non-Chinese Pharmaceutical CMOs: Distribution by Type of Powder FDF Manufactured
  • Table 16.23 Pharmaceutical CMO Manufacturing Facilities in Eastern China:
  • Table 16.24 Pharmaceutical CMO Manufacturing Facilities in Eastern China: Distribution by Type of Product
  • Table 16.25 Pharmaceutical CMO Manufacturing Facilities in Northern
  • Table 16.26 Pharmaceutical CMO Manufacturing Facilities in Northern China: Distribution by Type of Product
  • Table 16.27 Pharmaceutical CMO Manufacturing Facilities in Southern China: Distribution by Company Size
  • Table 16.28 Pharmaceutical CMO Manufacturing Facilities in Southern China: Distribution by Type of Product
  • Table 16.29 Big Pharma Players: Distribution by Number of Initiatives
  • Table 16.30 Big Pharma Players: Distribution by Year of Initiative
  • Table 16.31 Big Pharma Players: Distribution by Type of Initiative
  • Table 16.33 Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-February 2020
  • Table 16.34 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 16.35 Partnerships and Collaborations: Local and International Distribution
  • Table 16.36 Pharmaceutical Contract Manufacturing Installed Capacity in China: Distribution by Size of CMOs
  • Table 16.37 Pharmaceutical Contract Manufacturing Installed Capacity in China: Distribution by Location of Facility
  • Table 16.38 Capacity Analysis: Contract Pharmaceutical Capacity in Eastern China
  • Table 16.39 Capacity Analysis: Contract Pharmaceutical Capacity in Southcentral China
  • Table 16.40 Capacity Analysis: Contract Pharmaceutical Capacity in Northern China
  • Table 16.41 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
  • Table 16.42 Pharmaceutical Contract Manufacturing Services Market in China, 2025 and 2030, Distribution by Geography: Base Scenario (USD Billion)
  • Table 16.43 Pharmaceutical Contract Manufacturing Services Market in Eastern China, 2020-2030: Base Scenario (USD Billion)
  • Table 16.44 Pharmaceutical Contract Manufacturing Services Market in Southern China, 2020-2030: Base Scenario (USD Billion)
  • Table 16.45 Pharmaceutical Contract Manufacturing Services Market in Northern China, 2020-2030: Base Scenario (USD Billion)
  • Table 16.46 Pharmaceutical Contract Manufacturing Services Market in China, 2025 and 2030, Distribution by Type of Product (USD Billion)
  • Table 16.47 API Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
  • Table 16.48 API Contract Manufacturing Services Market in China, Distribution by Geography, 2025 and 2030: Base Scenario (USD Billion)
  • Table 16.49 API Contract Manufacturing Services Market in Eastern China, 2020-2030: Base Scenario (USD Billion)
  • Table 16.50 API Contract Manufacturing Services Market in Southern China, 2020-2030: Base Scenario (USD Billion)
  • Table 16.51 API Contract Manufacturing Services Market in Northern China, 2020-2030: Base Scenario (USD Billion)
  • Table 16.53 Drug Product Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
  • Table 16.52 Drug Product Contract Manufacturing Services Market in China, Distribution by Geography, 2025 and 2030: Base Scenario (USD Billion)
  • Table 16.54 Drug Product Contract Manufacturing Services Market in Eastern China, 2020-2030: Base Scenario (USD Billion)
  • Table 16.55 Drug Product Contract Manufacturing Services Market in Southern China, 2020-2030: Base Scenario (USD Billion)
  • Table 16.56 Drug Product Contract Manufacturing Services Market in Northern China, 2020-2030: Base Scenario (USD Billion)
  • Table 16.57 Drug Product Contract Manufacturing Services Market in China, Distribution by Type of Drug Product, 2025 and 2030, Base Scenario (USD Billion)
  • Table 16.58 Drug Product Contract Manufacturing Services Market in China, 2020-2030, Share of Solid Drug Product: Base Scenario (USD Billion)
  • Table 16.59 Drug Product Contract Manufacturing Services Market in China, 2020-2030, Share of Liquid and Semi Solid Drug Product: Base Scenario (USD Billion)
  • Table 16.60 Drug Product Contract Manufacturing Services Market in China, 2020-2030, Share of Injectable Drug Product: Base Scenario (USD Billion)
  • Table 16.61 Drug Product Contract Manufacturing Services Market in China, 2020-2030, Share of Other Drug Products: Base Scenario (USD Billion)
  • Table 16.62 Pharmaceutical Contract Manufacturing Services Market in China, Distribution by Scale of Operation, 2025 and 2030, Base Scenario (USD Billion)
  • Table 16.63 Clinical Scale Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
  • Table 16.64 Commercial Scale Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
  • Table 16.65 Pharmaceutical Contract Manufacturing Services Market in China, Distribution by Size of Manufacturers, 2025 and 2030, Base Scenario (USD Billion)
  • Table 16.66 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Small Companies: Base Scenario (USD Billion)
  • Table 16.67 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Mid-Sized Companies: Base Scenario (USD Billion)
  • Table 16.68 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Large / Very Large Companies: Base Scenario (USD Billion)

Listed Companies

  • 1. 2Y-Chem
  • 2. 3Waypharm
  • 3. ABA Chemicals
  • 4. AbbVie
  • 5. Aescu Pharma
  • 6. Agno Pharma
  • 7. Allychem
  • 8. Amgen
  • 9. Anhui Biochem Biopharmaceutical
  • 10. Anqiu Lu'an Pharmaceutical
  • 11. Antengene
  • 12. Apeloa
  • 13. APIchem
  • 14. APICMO
  • 15. Ark Biosciences
  • 16. Asymchem
  • 17. Aurisco Pharmaceutical
  • 18. Avery Chemical
  • 19. Beijing Kawin Technology
  • 20. Beijing Lunarsun Pharmaceutical
  • 21. Beijing Mediking Biopharm
  • 22. Beta Pharma
  • 23. BioDuro
  • 24. BioLingus
  • 25. BLD Pharm
  • 26. Bristol-Myers Squibb
  • 27. Broad Pharmaceutical
  • 28. C & O Pharmaceutical Technology
  • 29. CARBOGEN AMCIS
  • 30. Catalent Pharma Solutions
  • 31. Changzhou Carbochem
  • 32. Changzhou Keylab Chemical
  • 33. ChemFuture PharmaTech
  • 34. ChemPartner
  • 35. Chemsigma International
  • 36. Chemspec Chemicals
  • 37. Chemwill Asia
  • 38. China Pharmaceutical Research and Development Center
  • 39. Chinese Peptide
  • 40. Chiral Quest
  • 41. Chongqing Huabang Shengkai Pharmaceutical
  • 42. Chongqing Pharmaceutical Research Institute
  • 43. Cipla
  • 44. Codexis
  • 45. ComWin International
  • 46. DC Chemicals
  • 47. Dishman Group
  • 48. Dizal Pharmaceutical
  • 49. Dorrapharma
  • 50. DSL Chemicals
  • 51. Enantiotech
  • 52. Enbridge PharmTech
  • 53. EOC Pharma
  • 54. Esteve Huayi Pharmaceutical
  • 55. FarmaSino Pharmaceutical
  • 56. Fine Industries
  • 57. Flamma
  • 58. Fountainbridge
  • 59. Fresenius Kabi
  • 60. GIHI CHEMICALS
  • 61. Gilead Sciences
  • 62. GlaxoSmithKline
  • 63. Hangzhou DayangChem
  • 64. Hangzhou Hysen Pharma
  • 65. Hangzhou Panyu Chemical
  • 66. Hangzhou Pharmco
  • 67. Hangzhou Rongda Pharm & Chem
  • 68. HangZhou Think Chemical
  • 69. HD Biosciences
  • 70. Hebei BRANT Pharmaceutical
  • 71. Hebei Jiheng Pharmaceutical
  • 72. Hetero
  • 73. Hovione
  • 74. Huayi Pharmaceuticals
  • 75. Hubei Biocause Pharmaceutical
  • 76. Hybio Pharmaceutical
  • 77. Impact Therapeutics
  • 78. Infoark
  • 79. Jiangsu Allyrise Pharmaceutical
  • 80. Jiangsu Baozong & Baoda Pharmachem
  • 81. Jiangsu Hansyn Pharmaceutical
  • 82. Jiangsu Quality Horizons Pharmtech
  • 83. Jiangxi Fushine Pharmaceutical
  • 84. JOINN Laboratories
  • 85. Junye Pharmaceutical
  • 86. Kingchem Life Sciences
  • 87. Krka
  • 88. Laviana Pharma
  • 89. LEAPChem
  • 90. Lianhetech
  • 91. Lianhua Technology
  • 92. Lonza
  • 93. Luna Chemicals
  • 94. Medichem
  • 95. Merck
  • 96. Nanjing Pharmatechs
  • 97. NFTZ Alchem International
  • 98. Ningbo Menovo Pharmaceutical
  • 99. Novartis
  • 100. Novasep
  • 101. Pfizer
  • 102. Pfizer CentreOne
  • 103. PharmaBlock Sciences
  • 104. PharmAgra Labs
  • 105. Phoenix Molecular Designs
  • 106. Pi chemicals
  • 107. Piramal Pharma Solutions
  • 108. Porton Pharma Solutions
  • 109. Prisun Pharmachem
  • 110. Qidong Accela ChemBio
  • 111. Qingdao Kingway Pharmtech
  • 112. Quantum
  • 113. Raybow Pharm
  • 114. Roche
  • 115. SAGECHEM
  • 116. Saniver
  • 117. Sanofi
  • 118. SciAnda (Changshu) Pharmaceuticals
  • 119. Seacross Pharmaceuticals
  • 120. Shandong Keyuan Pharmaceutical
  • 121. Shandong Luxi Pharmaceutical
  • 122. Shandong Xinhua Pharmaceutical
  • 123. Shanghai Acebright Pharmaceuticals
  • 124. Shanghai Ansion pharma Technology
  • 125. Shanghai Fosun Pharmaceutical
  • 126. Shanghai Hohance Chemical
  • 127. Shanghai Pansopharm Technology
  • 128. Shanghai Ruiyi Medical Tech
  • 129. Shenzhen Jianyuan Pharmaceutical Technology
  • 130. Siegfried
  • 131. Sihuan Pharmaceutical
  • 132. Sinolite
  • 133. STA Pharmaceutical
  • 134. Sundia MediTech
  • 135. Sunwell
  • 136. Suzhou Chung-Hwa Chemical & Pharmaceutical Industrial
  • 137. Suzhou Novartis Pharmaceutical Technology
  • 138. Tai Heng Industry
  • 139. TCI (Shanghai) Development
  • 140. Tesaro
  • 141. TIEN (Tianjin) Pharmaceutical
  • 142. Topharman Shanghai
  • 143. Venturepharma
  • 144. Vesino
  • 145. Vifor Pharma
  • 146. Vitruvias Therapeutic
  • 147. ViWA
  • 148. Viwit Pharmaceuticals
  • 149. Wisdom Pharmaceutical
  • 150. WuXi AppTec
  • 151. Xianju pharma
  • 152. XINXIANG BEST PHARMACEUTICAL
  • 153. YaoPharma
  • 154. Yiling Pharmaceutical
  • 155. Zhejiang Candorly Pharmaceutical
  • 156. Zhejiang Changming Pharmaceutical
  • 157. Zhejiang Dongjian Pharmaceutical
  • 158. Zhejiang Excel Pharmaceutical
  • 159. Zhejiang Haizhou Pharmaceutical
  • 160. Zhejiang Hisun Pharmaceutical
  • 161. Zhejiang Huahai Pharmaceutical
  • 162. Zhejiang Jiuzhou Pharmaceutical
  • 163. Zhejiang Langhua Pharmaceutical
  • 164. Zhejiang Tianyu Pharmaceutical
  • 165. Zhejiang Yongtai Technology
  • 166. ZHIWE ChemTech
目次

Example Insights:

Overview:

Small molecule drugs represent nearly 90% of pharmaceutical products available in the market. In fact, in 2019, the FDA's Center for Drug Evaluation and Research approved 48 drugs, of which, 67% were small molecules. However, drug development and manufacturing is a cost intensive process, and is, at times, characterized by the need for advanced capabilities and specialized facilities, which are not possible for all developer companies to build in-house. This has compelled many of the smaller companies to outsource a significant part of their manufacturing operations to contract service providers. Pharmaceutical contract manufacturing organizations (CMOs) offer a wide range of services, ranging from process R&D, and clinical / commercial scale manufacturing of APIs, intermediates and FDFs. Some of the benefits of engaging manufacturing service providers include access to larger production capacities, cost savings (for innovator companies) and reductions in time-to-market. In this context, the advantages of outsourcing to emerging global regions, especially in Asia, are well known. A number of western drug developers have already demonstrated the preference to outsource their manufacturing operations to CMOs or CDMOs in China.

Over the past few decades, the pharmaceutical market in China has evolved into the second largest in the world; as per certain industry experts, it is estimated to surpass USD 300 billion by the end of 2020. Similarly, the contract manufacturing market in the region has also grown into a prominent and promising segment of the pharmaceutical industry. The relatively lower manufacturing costs, availability of cheap and skilled labor, and a supportive regulatory landscape, have led to the establishment of various pharmaceutical manufacturing facilities in China by both Chinese and non-China based service providers. The number of FDA approved API manufacturing facilities in the region has doubled during the period 2010-2019. In fact, as of October 2019, 13% of FDA approved pharmaceutical manufacturing facilities are situated in China. These service providers are focused on investing in the development of the necessary capabilities and capacity to stay ahead of the competition in this field. In light of the aforementioned facts, China has been one of the top preferences of pharmaceutical companies for API and FDF manufacturing projects, since the past few years.

We believe that, the changing supply chain scenario due to the recent COVID-19 outbreak is likely to have a prominent impact on the global contract manufacturing industry, including China, in the short term. Having said that, the steps being taken by the pharma players and contract manufacturers are likely to help stakeholders absorb this impact. As pharma companies resume full-scale operation after the coronavirus outbreak, the demand for large-scale contract manufacturing is expected to increase significantly.

Scope of the Report:

The "China Pharmaceutical Contract Manufacturing Services Market, 2020-2030" report features an extensive study of the current market landscape and future opportunities associated with the pharmaceutical contract manufacturing market in China. The study also features a detailed analysis, highlighting the capabilities of pharmaceutical CMOs in this region. Amongst other elements, the report features:

  • A review of the current market landscape of companies offering pharmaceutical contract manufacturing services in China, along with information on year of establishment, company size, location of headquarters, type of product (active pharmaceutical ingredients (APIs), intermediates and finished dosage formulations (FDFs)), type of FDFs, type of primary packaging and number of manufacturing facilities.
  • A detailed landscape of the pharmaceutical manufacturing facilities in China, including an analysis based on location of these facilities, highlighting key manufacturing hubs.
  • A brief discussion of various guidelines laid down by regulatory authorities in China for the manufacturing of pharmaceuticals. It also provides information on various challenges, related to regulatory scrutiny, faced by pharmaceutical manufacturers in China.
  • Brief profiles of key players that offer a diverse range of capabilities for the manufacturing of pharmaceutical products in China. Each profile includes an overview of the company, information related to its pharmaceutical manufacturing service portfolio, details related to its manufacturing facilities, recent developments, and an informed future outlook.
  • A review of the pharmaceutical manufacturing related initiatives of the top 10 big pharma players (shortlisted from the top companies of 2019 by revenues), featuring a [A] analysis by investments made, with detailed information on investments related to R&D centers and manufacturing facilities in established and emerging regions of China, [B] Harvey ball framework, presenting a summary of all initiatives, and [C] a heat map representation highlighting the yearly distribution of the initiatives undertaken by each company.
  • A case study of the key recent developments (including partnerships and acquisitions) pertaining to the manufacturing of pharmaceutical drugs, during 2014-2020 (till February), based on several parameters, such as year of partnership, type of partnership and geography.
  • A detailed capacity analysis based on the individual reactor capacities of various industry stakeholders, taking into consideration parameters, such as company size (small-sized, mid-sized, large and very large), and location of the manufacturing facility (Eastern China, Southern China and Northern China).
  • A discussion on industry affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the evolution of this field. It also includes a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on industry dynamics.
  • A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on various parameters, such as growth of the overall pharmaceutical drugs market in China, cost of goods sold, and direct manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2020-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] key geographical regions (Eastern China, Southern China, Northern China), [B] type of product (API and drug product), [C] type of drug product (solid, liquid / semi-solid, injectables, others), [D] scale of operation (clinical and commercial), [E] company size (small-sized, mid-sized, large / very large. To account for the uncertainties associated with the growth of the pharmaceutical drugs contract manufacturing market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in this study were also influenced by discussions conducted with stakeholders in this domain. All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

Chapter Outlines:

Chapter 2 provides an executive summary of the key insights captured in our research. The summary offers a high-level view on the likely evolution of pharmaceutical contract manufacturing services market in China, in the short-mid and long term.

Chapter 3 is a general introduction to various type of manufacturers engaged in the pharmaceutical domain. It also includes a brief overview on the concept of contract manufacturing and a general discussion on the evolution of contract services in the pharmaceutical industry. The chapter features an exhaustive list of services offered by CMOs. Further, it highlights the current contract manufacturing scenario in China, along with the advantages and disadvantages associated with choosing a China based CMO as a partner.

Chapter 4 is a case study comparing the key characteristics of large and small molecule drugs, along with information on the steps involved in their respective manufacturing processes. In addition, it highlights the information on the key manufacturing challenges associated with small molecules and large molecules.

Chapter 5 provides an overview of the pharmaceutical contract manufacturing landscape of companies that claim to offer small molecule API, intermediate and FDF manufacturing services. It includes analysis based on a number of relevant parameters, such as year of establishment, company size, location of headquarters, type of product (APIs, intermediates and FDFs), type of FDFs, type of packaging (primary packaging and secondary packaging), and number of China-based manufacturing facilities.

Chapter 6 provides a detailed landscape of pharmaceutical manufacturing facilities in China. It includes analysis and map representations based on location of these facilities, highlighting key provinces as manufacturing hubs.

Chapter 7 features a brief discussion on the regulatory guidelines related to the pharmaceutical manufacturing in China. It also highlights points related to the various challenges, related to regulatory scrutiny, faced by pharmaceutical manufacturers in China.

Chapter 8 includes detailed profiles of key players that offer a diverse range of capabilities for the manufacturing of pharmaceutical products in China. Each profile features a brief overview of the company, details related to its manufacturing-related service portfolio, details related to its manufacturing facilities, recent developments, and an informed future outlook.

Chapter 9 provides a detailed analysis of pharmaceutical manufacturing related initiatives of the top 10 big pharma players (shortlisted from the top companies of 2019 by revenues), featuring a [A] facility investment analysis with detailed information on R&D centers and manufacturing facilities in established and emerging regions of China, [B] Harvey ball framework presenting the summary of manufacturing initiatives undertaken by big pharma players in China, and [C] heat map representation representing the year-wise distribution of the initiatives undertaken by each company.

Chapter 10 represents a case study of the key recent activities of the CMOs from 2017 to February 2020 (including partnerships and acquisitions) pertaining to the manufacturing of pharmaceutical drugs. It includes analysis based on several parameters, such as year of partnership, type of partnership and geographical activity of the partnerships.

Chapter 11 features an estimate of the overall installed reactor capacity of CMOs. The analysis based on the individual reactor capacities of various industry stakeholders, taking into consideration parameters, such as company size (small-sized, mid-sized, large and very large), and location of the manufacturing facility (Eastern China, Southern China and Northern China).

Chapter 12 presents a discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry's evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry.

Chapter 13 features an elaborate market forecast analysis highlighting the likely growth of pharmaceutical contract manufacturing market in China, till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] key geographical regions (Eastern China, Southern China, Northern China), [B] type of product (API and drug product), [C] type of drug product (solid, liquid / semi-solid, injectables, others), [D] scale of operation (clinical and commercial), [E] company size (small-sized, mid-sized, large / very large). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

Chapter 14 highlights the effect of coronavirus outbreak on the global pharmaceutical industry. It includes a brief discussion on the short-term and long-term impact of COVID-19 upsurge on the supply chain and market opportunity for drug developers and CMOs. In addition, it includes a brief section on strategies and action plans that pharma companies are likely to adopt in order to prepare for supply chain disruptions in future.

Chapter 15 is a summary of the overall report. It includes key takeaways related to research and analysis from the report in an infographic format.

Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 17 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Overview of the Pharmaceutical Contract Manufacturing
  • 3.3. Evolution of the Pharmaceutical Contract Manufacturing Industry
    • 3.3.1. Traditional CMOs
    • 3.3.2. Modern CMOs
  • 3.4 Need for Outsourcing in the Pharmaceutical Industry
  • 3.5. Services Offered by CMOs
  • 3.6. Pharmaceutical Contract Manufacturing Scenario in China
  • 3.7. Advantages and Challenges associated with Outsourcing Pharmaceutical Manufacturing to China-based CMOs

4. CASE STUDY: COMPARISON OF SMALL MOLECULES AND LARGE MOLECULES

  • 4.1. Chapter Overview
  • 4.2. Small Molecule and Large Molecule Drugs / Therapies
    • 4.2.1. Comparison of Key Characteristics
    • 4.2.2. Comparison of Manufacturing Processes
    • 4.2.3. Comparison of Key Manufacturing-related Challenges

5. MARKET OVERVIEW

  • 5.1. Chapter Overview
  • 5.2. Chinese Pharmaceutical CMOs with Manufacturing Facilities in China: List of Companies
    • 5.2.1. Analysis by Year of Establishment
    • 5.2.2. Analysis by Company Size
    • 5.2.3. Analysis by Location of Headquarters
    • 5.2.4. Analysis by Type of Product (API and FDF)
      • 5.2.4.1. Analysis by Type of Product and Location of Headquarters
    • 5.2.5. Analysis by Highest Scale of Operation
    • 5.2.6. Analysis by Type of FDF
      • 5.2.6.1. Analysis by Type of Solid FDF
      • 5.2.6.2. Analysis by Type of Liquid FDF
      • 5.2.6.3. Analysis by Type of Powder FDF
      • 5.2.6.4. Analysis by Type of Semi-Solid FDF
      • 5.2.6.5. Analysis by Type of FDF and Region
    • 5.2.7. Analysis by Type of Primary Packaging
  • 5.3. Non-Chinese Pharmaceutical CMOs with Manufacturing Facilities in China: List of Companies
    • 5.3.1. Analysis by Year of Establishment
    • 5.3.2. Analysis by Company Size
    • 5.3.3. Analysis by Location of Headquarters
    • 5.3.4. Analysis by Type of Product (API and FDF)
      • 5.3.4.1. Analysis by Type of Product and Region
    • 5.3.5. Analysis by Highest Scale of Operation
    • 5.3.6. Analysis by Type of FDF
      • 5.3.6.1. Analysis by Type of Solid FDF
      • 5.3.6.2. Analysis by Type of Liquid FDF
      • 5.3.6.3. Analysis by Type of Powder FDF
      • 5.3.6.5. Analysis by Type of FDF and Region

6. MANUFACTURING FACILITIES OF PHARMACEUTICAL CMOs IN CHINA

  • 6.1. Chapter Overview
  • 6.2. Pharmaceutical CMO Manufacturing Facilities in China
    • 6.2.1. Facilities in Eastern China
      • 6.2.1.1. Pharmaceutical CMO Manufacturing Facilities in Eastern China: Analysis by Location of Facility
      • 6.2.1.2. Pharmaceutical CMO Manufacturing Facilities in Eastern China: Analysis by Company Size and Type of Product
    • 6.2.2. Facilities in Northern China
      • 6.2.2.1. Pharmaceutical CMO Manufacturing Facilities in Northern China: Analysis by Location of Facility
      • 6.2.2.2. Pharmaceutical CMO Manufacturing Facilities in Northern China: Analysis by Company Size and Type of Product
    • 6.2.3. Facilities in Southern China
      • 6.2.3.1. Pharmaceutical CMO Manufacturing Facilities in Southern China: Analysis by Location of Facility
      • 6.2.3.2. Pharmaceutical CMO Manufacturing Facilities in Southern China: Analysis by Company Size and Type of Product

7. PHARMACEUTICAL MANUFACTURING REGULATIONS IN CHINA

  • 7.1. Chapter Overview
    • 7.1.1. Health Authorities in China
    • 7.1.2. Overview of Regulatory Guidelines in China

8. COMPANY PROFILES

  • 8.1. Chapter Overview
  • 8.2. 2Y-Chem
    • 8.2.1. Company Overview
    • 8.2.2. Service Portfolio
    • 8.2.3. Recent Developments and Future Outlook
  • 8.3. Aurisco Pharmaceutical
    • 8.3.1. Company Overview
    • 8.3.2. Service Portfolio
    • 8.3.3. Recent Developments and Future Outlook
  • 8.4. ChemPartner
    • 8.4.1. Company Overview
    • 8.4.2. Service Portfolio
    • 8.4.4. Recent Developments and Future Outlook
  • 8.5. Dorrapharma
    • 8.5.1. Company Overview
    • 8.5.2. Service Portfolio
    • 8.5.4. Recent Developments and Future Outlook
  • 8.6. Hubei Biocause Pharmaceutical
    • 8.6.1. Company Overview
    • 8.6.2. Service Portfolio
    • 8.6.3. Recent Developments and Future Outlook
  • 8.7. Infoark
    • 8.7.1. Company Overview
    • 8.7.2. Service Portfolio
    • 8.7.3. Recent Developments and Future Outlook
  • 8.8. Ningbo Menovo Pharmaceutical
    • 8.8.1. Company Overview
    • 8.8.2. Service Portfolio
    • 8.8.3. Recent Developments and Future Outlook
  • 8.9. Shandong Xinhua Pharmaceutical
    • 8.9.1. Company Overview
    • 8.9.2. Service Portfolio
    • 8.9.3. Recent Developments and Future Outlook
  • 8.10. Shanghai Acebright Pharmaceuticals
    • 8.10.1. Company Overview
    • 8.10.2. Service Portfolio
    • 8.10.3. Recent Developments and Future Outlook
  • 8.11. STA Pharmaceutical
    • 8.11.1. Company Overview
    • 8.11.2. Service Portfolio
    • 8.11.3. Recent Developments and Future Outlook
  • 8.12. Zhejiang Huahai Pharmaceutical
    • 8.12.1. Company Overview
    • 8.12.2. Service Portfolio
    • 8.12.4. Recent Developments and Future Outlook

9. BIG PHARMA INITIATIVES IN CHINA

  • 9.1. Chapter Overview
  • 9.2. Big Pharma Players: List of Initiatives
    • 9.2.1. Analysis by Number of Initiatives
    • 9.2.2. Analysis by Year of Initiative
    • 9.2.3. Analysis by Company and Year of Initiative
    • 9.2.4. Analysis by Type of Initiative
  • 9.3. Benchmark Analysis of Big Pharmaceutical Players
    • 9.3.1. Harvey Ball Analysis: Summary of Investments Made
    • 9.3.2. Geographical Analysis by Investments Made (Facility Specific)

10. CASE STUDY: RECENT PARTNERSHIP TRENDS

  • 10.1. Chapter Overview
  • 10.2. Partnership Models
  • 10.3. CMOs with Manufacturing Facilities in China: List of Recent Partnerships
    • 10.3.1. Analysis by Year of Partnership
    • 10.3.2. Analysis by Type of Partnership
    • 10.3.3. Analysis by Geography
  • 10.4. CMOs with Manufacturing Facilities in China: Mapping Partnerships

11. CAPACITY ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Key Assumptions and Methodology
  • 11.3. CMOs with Manufacturing Facilities in China: Installed Capacity
    • 11.3.1. Analysis by Company Size
    • 11.3.2. Analysis by Location of Chinese Manufacturing Facilities
      • 11.3.2.1. Capacity Analysis: Eastern China
      • 11.3.2.2. Capacity Analysis: Southcentral China
      • 11.3.2.3. Capacity Analysis: Northern China

12. SWOT ANALYSIS

  • 12.1. Chapter Overview
  • 12.2 Strengths
  • 12.3. Weakness
  • 12.4. Opportunities
  • 12.5. Threats
  • 12.6. Comparison of SWOT Factors

13. MARKET FORECAST

  • 13.1. Chapter Overview
  • 13.2. Forecast Methodology and Key Assumptions
  • 13.3. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030
  • 13.4. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Geography
    • 13.4.1. Pharmaceutical Contract Manufacturing Services Market in Eastern China, 2020-2030
    • 13.4.2. Pharmaceutical Contract Manufacturing Services Market in Southern China, 2020-2030
    • 13.4.3. Pharmaceutical Contract Manufacturing Services Market in Northern China, 2020-2030
  • 13.5. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Type of Product
    • 13.5.1. API Contract Manufacturing Services Market in China, 2020-2030
      • 13.5.1.1. API Contract Manufacturing Services Market in China, 2020-2030: Distribution by Geography
        • 13.5.1.1.1. API Contract Manufacturing Services Market in Eastern China, 2020-2030
        • 13.5.1.1.2. API Contract Manufacturing Services Market in Southern China, 2020-2030
        • 13.5.1.1.3. API Contract Manufacturing Services Market in Northern China, 2020-2030
    • 13.5.2. Drug Product Contract Manufacturing Services Market in China, 2020-2030
      • 13.5.2.1. Drug Product Contract Manufacturing Services Market in China, 2020-2030: Distribution by Geography
        • 13.5.2.1.1. Drug Product Contract Manufacturing Services Market in Eastern China, 2020-2030
        • 13.5.2.1.2. Drug Product Contract Manufacturing Services Market in Southern China, 2020-2030
        • 13.5.2.1.3. Drug Product Contract Manufacturing Services Market in Northern China, 2020-2030
      • 13.5.2.2. Drug Product Contract Manufacturing Services Market in China, 2020-2030: Distribution by Type of Drug Product
        • 13.5.2.2.1. Drug Product Contract Manufacturing Services Market in China, 2020-2030: Share of Solid Drug Product
        • 13.5.2.2.2. Drug Product Contract Manufacturing Services Market in China, 2020-2030: Share of Liquid and Semi Solid Drug Product
        • 13.5.2.2.3. Drug Product Contract Manufacturing Services Market in China, 2020-2030: Share of Injectable Drug Product
        • 13.5.2.2.4. Drug product Contract Manufacturing Services Market in China, 2020-2030: Share of Other Drug Products
  • 13.6. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Scale of Operation
    • 13.6.1. Clinical Scale Contract Manufacturing Services Market in China, 2020-2030
    • 13.6.2. Commercial Scale Contract Manufacturing Services Market in China, 2020-2030
  • 13.7. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Size of Manufacturers
    • 13.7.1. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Small Companies
    • 13.7.2. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Mid-sized Companies
    • 13.7.3. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Large / Very Large Companies
  • 13.8. Concluding Remarks

14. CASE STUDY: IMPACT OF CORONAVIRUS OUTBREAK

  • 15.1. Chapter Overview
  • 15.2. Evaluation of Impact of COVID-19 Outbreak
    • 15.2.1. Initiatives and Opinions of Key Players
      • 15.2.1.1. Wuxi AppTec
      • 15.2.1.2. Porton Pharma Solutions
      • 15.2.1.3. Lonza
    • 15.2.2 Impact on China Pharmaceutical CMO Market Opportunity
  • 15.3. Key Strategies to Adopt: A Bird's Eye View
    • 15.3.1. Immediate Steps
    • 15.3.2. Short / Long Term Steps

15. CONCLUSION

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.